RT Journal Article
SR Electronic
T1 Immunodominant B cell epitope in a hotspot mutation site and mechanism of immune escape for SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.11.21253399
DO 10.1101/2021.03.11.21253399
A1 Oliveira, Jamille Ramos
A1 Machado, Rafael Rahal G.
A1 Arcuri, Helen Andrade
A1 Magawa, Jhosiene Yukari
A1 Daher, Isabela Pazotti
A1 Urbanski, Alysson Henrique
A1 Händel Schmitz, Gabriela Justamante
A1 Silva, Roberto Carlos Vieira
A1 Durigon, Edison Luiz
A1 Boscardin, Silvia Beatriz
A1 Rosa, Daniela Santoro
A1 Schechtman, Deborah
A1 Nakaya, Helder I
A1 Cunha-Neto, Edecio
A1 Gadermaier, Gabriele
A1 Coelho, Verônica
A1 Santos, Keity Souza
A1 Kalil, Jorge
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/04/17/2021.03.11.21253399.abstract
AB Recent SARS-CoV-2 variants pose important concerns due to their higher transmissibility (1) and escape (2) from previous infections or vaccine-induced neutralizing antibodies (nAb). The receptor binding domain (RBD) of the Spike protein is a major nAb target (3), but data on its B cell epitopes are still lacking. Using a peptide microarray, we identified an immunodominant epitope (S415-429) recognized by 68% of sera from 71 convalescent Brazilians infected with the ancestral variant. In contrast with previous studies, we have identified a linear IgG and IgA antibody binding epitope within the RBD. IgG and IgA antibody levels for this epitope positively correlated with nAb titers, suggesting a potential target of antibody neutralizing activity. Interestingly, this immunodominant RBD region harbors the mutation hotspot site K417 present in P.1 (K417T) and B.1.351 (K417N) variants. In silico simulation analyses indicate impaired RBD binding to nAb in both variants and that a glycosylation in the B.1.351 417N could further hinder antibody binding as compared to the K417T mutation in P.1. This is in line with published data showing that nAb from either convalescents or anti-CoV-2 vaccinees are less effective towards B.1.351 than for P.1. Our data support the occurrence of immune pressure and selection involving this immunodominant epitope that may have critically contributed to the recent COVID-19 marked rise in Brazil and South Africa, and pinpoint a potential additional immune escape mechanism for SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by FAPESP project N. 2020/05256-7 and FINEP grant N. 01.20.0009.00.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by CAPPesq (Comissao de Etica Para Analise de Projetos de Pesquisa do HC-FMUSP) and CONEP (Comissao Nacional de Etica em Pesquisa) (CAAE: 30155220.3.0000.0068). All study participants signed informed consents.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data.